{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:32:44Z","timestamp":1770823964732,"version":"3.50.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-024-01102-x","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T14:51:49Z","timestamp":1733323909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Challenges for the implementation of injectable opioid agonist treatment: a scoping review"],"prefix":"10.1186","volume":"21","author":[{"given":"Tanja","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Akartuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Michael","family":"Krausz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"1102_CR1","unstructured":"WHO. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. In. Geneva: WHO; 2009."},{"issue":"7","key":"1102_CR2","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/add.14171","volume":"113","author":"N Bansback","year":"2018","unstructured":"Bansback N, Guh D, Oviedo-Joekes E, Brissette S, Harrison S, Janmohamed A, Krausz M, MacDonald S, Marsh DC, Schechter MT, et al. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Addiction. 2018;113(7):1264\u201373.","journal-title":"Addiction"},{"issue":"2","key":"1102_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/bcp.12051","volume":"77","author":"J Bell","year":"2014","unstructured":"Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol. 2014;77(2):253\u201363.","journal-title":"Br J Clin Pharmacol"},{"key":"1102_CR4","volume-title":"Medications for opioid Use Disorder Save lives","author":"National Academies of Sciences E, and Medicine","year":"2019","unstructured":"National Academies of Sciences E, and Medicine. The effectiveness of medication-based treatment for opioid Use Disorder. Medications for opioid Use Disorder Save lives. edn. Washington, DC: National Academies; 2019."},{"issue":"1","key":"1102_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12954-021-00473-9","volume":"18","author":"M Busch","year":"2021","unstructured":"Busch M, Klein C, Uhl A, Haltmayer H, Cabanis M, Westenberg JN, Vogel M, Krausz RM. Retention in the Austrian opioid agonist treatment system: a national prospective cohort study. Harm Reduct J. 2021;18(1):25.","journal-title":"Harm Reduct J"},{"key":"1102_CR6","volume-title":"National injectable opioid agonist treatment for opioid use disorder operational guidance","author":"CRISM","year":"2019","unstructured":"CRISM. National injectable opioid agonist treatment for opioid use disorder operational guidance. In. Vancouver (BC): Canadian Research Initiative in Substance Misuse (CRISM); 2019."},{"key":"1102_CR7","doi-asserted-by":"crossref","unstructured":"Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Reviews. 2011(12).","DOI":"10.1002\/14651858.CD003410.pub3"},{"issue":"1","key":"1102_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","volume":"207","author":"J Strang","year":"2015","unstructured":"Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, Lintzeris N, Bell J, Pirona A, Oviedo-Joekes E, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015;207(1):5\u201314.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"1102_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00408-021-00456-4","volume":"199","author":"CM Cook","year":"2021","unstructured":"Cook CM, Simpson SQ, Satterwhite L. Excipient-Induced Pulmonary Vascular Disease: an underrecognized and deadly complication of opioid addiction. Lung. 2021;199(4):363\u20138.","journal-title":"Lung"},{"issue":"1","key":"1102_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000496112","volume":"25","author":"F Lugoboni","year":"2019","unstructured":"Lugoboni F, Zamboni L, Cibin M, Tamburin S. Gruppo InterSert Di Collaborazione Scientifica Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in patients under opioid maintenance treatment: a cross-sectional Multicentre Study. Eur Addict Res. 2019;25(1):10\u20139.","journal-title":"Eur Addict Res"},{"issue":"5","key":"1102_CR11","doi-asserted-by":"publisher","first-page":"W506","DOI":"10.2214\/AJR.14.12582","volume":"203","author":"VT Nguyen","year":"2014","unstructured":"Nguyen VT, Chan ES, Chou S-HS, Godwin JD, Fligner CL, Schmidt RA, Pipavath SNJ. Pulmonary effects of IV injection of crushed oral tablets: Excipient Lung Disease. Am J Roentgenol. 2014;203(5):W506\u201315.","journal-title":"Am J Roentgenol"},{"issue":"1","key":"1102_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12954-023-00866-y","volume":"20","author":"C Bertin","year":"2023","unstructured":"Bertin C, D\u00e8cle P, Chappard P, Roux P, Authier N. People who inject oral morphine favor experimentation with injectable opioid substitution. Harm Reduct J. 2023;20(1):130.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1102_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12954-023-00781-2","volume":"20","author":"C Bertin","year":"2023","unstructured":"Bertin C, Montigne E, Teixeira S, Ferrer F, Lauwerie L, Richard D, Authier N. Intravenous misuse of slow-release oral morphine capsules: how much morphine is injected? Harm Reduct J. 2023;20(1):59.","journal-title":"Harm Reduct J"},{"issue":"12","key":"1102_CR14","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1111\/bcp.14082","volume":"86","author":"C Bertin","year":"2020","unstructured":"Bertin C, Delorme J, Riquelme M, Peyri\u00e8re H, Brousse G, Eschalier A, Ardid D, Chenaf C, Authier N. Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients. Br J Clin Pharmacol. 2020;86(12):2338\u201348.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1102_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.drugalcdep.2005.01.005","volume":"79","author":"J Rehm","year":"2005","unstructured":"Rehm J, Frick U, Hartwig C, Gutzwiller F, Gschwend P, Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994\u20132000. Drug Alcohol Depend. 2005;79(2):137\u201343.","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"1102_CR16","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/j.addbeh.2013.05.008","volume":"38","author":"M Vogel","year":"2013","unstructured":"Vogel M, Kn\u00f6pfli B, Schmid O, Prica M, Strasser J, Prieto L, Wiesbeck GA, D\u00fcrsteler-MacFarland KM. Treatment or high: benzodiazepine use in patients on injectable heroin or oral opioids. Addict Behav. 2013;38(10):2477\u201384.","journal-title":"Addict Behav"},{"issue":"5","key":"1102_CR17","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/10826084.2016.1246571","volume":"52","author":"D Krause","year":"2017","unstructured":"Krause D, Pl\u00f6rer D, Koller G, Martin G, Winter C, Adam R, Canolli M, Al-Iassin J, Musselmann R, Walcher S, et al. High concomitant misuse of fentanyl in subjects on opioid maintenance treatment. Subst Use Misuse. 2017;52(5):639\u201345.","journal-title":"Subst Use Misuse"},{"key":"1102_CR18","volume-title":"CADTH rapid response report: summary with critical appraisal","author":"S Banerjee","year":"2020","unstructured":"Banerjee S, Wright M-D. Injectable opioid agonist treatment for patients with opioid dependence: a review of clinical and cost-effectiveness. CADTH rapid response report: summary with critical appraisal. Ottawa: CADTH; 2020."},{"key":"1102_CR19","unstructured":"EMCDDA. New heroin-assisted treatment. In. Luxembourg: Publications Office of the European Union; 2012."},{"issue":"13","key":"1102_CR20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s40265-018-0962-y","volume":"78","author":"J Bell","year":"2018","unstructured":"Bell J, Belackova V, Lintzeris N. Supervised injectable opioid treatment for the management of opioid dependence. Drugs. 2018;78(13):1339\u201352.","journal-title":"Drugs"},{"key":"1102_CR21","doi-asserted-by":"publisher","first-page":"111036","DOI":"10.1016\/j.drugalcdep.2023.111036","volume":"254","author":"T Schwarz","year":"2024","unstructured":"Schwarz T, Anzenberger J, Busch M, Gmel G, Kraus L, Krausz M, Labhart F, Meyer M, Schaub MP, Westenberg JN, et al. Opioid agonist treatment in transition: a cross-country comparison between Austria, Germany and Switzerland. Drug Alcohol Depend. 2024;254:111036.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1102_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12954-022-00644-2","volume":"19","author":"M Meyer","year":"2022","unstructured":"Meyer M, Westenberg JN, Strasser J, D\u00fcrsteler KM, Lang UE, Krausz M, Vogel M. Nasal administration of diacetylmorphine improved the adherence in a patient receiving heroin-assisted treatment. Harm Reduct J. 2022;19(1):63.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1102_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12954-023-00731-y","volume":"20","author":"M Vogel","year":"2023","unstructured":"Vogel M, Meyer M, Westenberg JN, Kormann A, Simon O, Salim Hassan Fadlelseed R, Kurmann M, Br\u00f6er R, Devaud N, Sanwald U, et al. Safety and feasibility of intranasal heroin-assisted treatment: 4-week preliminary findings from a Swiss multicentre observational study. Harm Reduct J. 2023;20(1):2.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1102_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332.","journal-title":"Int J Soc Res Methodol"},{"issue":"5","key":"1102_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.amepre.2009.02.002","volume":"36","author":"DJ Bowen","year":"2009","unstructured":"Bowen DJ, Kreuter M, Spring B, Cofta-Woerpel L, Linnan L, Weiner D, Bakken S, Kaplan CP, Squiers L, Fabrizio C, et al. How we Design Feasibility studies. Am J Prev Med. 2009;36(5):452\u20137.","journal-title":"Am J Prev Med"},{"issue":"7","key":"1102_CR26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, et al. PRISMA Extension for scoping reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"key":"1102_CR27","volume-title":"Qualitative Research Practice. A guide for Social Science Students and Researchers","author":"J Ritchie","year":"2014","unstructured":"Ritchie J, Lewis J, McNaughton Nicholls C, Ormston R. Qualitative Research Practice. A guide for Social Science Students and Researchers. 2nd ed. London: Sage; 2014.","edition":"2"},{"issue":"1","key":"1102_CR28","doi-asserted-by":"publisher","first-page":"2196435","DOI":"10.1080\/07853890.2023.2196435","volume":"55","author":"ST Allen","year":"2023","unstructured":"Allen ST, Schneider KE, Rouhani S, White RH, Morris M, Owczarzak J, Sherman SG. Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA). Ann Med. 2023;55(1):2196435.","journal-title":"Ann Med"},{"issue":"4","key":"1102_CR29","first-page":"434","volume":"30","author":"L Archambault","year":"2023","unstructured":"Archambault L, Goyer M-\u00c8, Sabetti J, Perreault M. Implementing injectable opioid agonist treatment: a survey of professionals in the field of opioid use disorders. Drugs: Educ Prev Policy. 2023;30(4):434\u201342.","journal-title":"Drugs: Educ Prev Policy"},{"issue":"5418","key":"1102_CR30","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1126\/science.284.5418.1277","volume":"284","author":"G Bammer","year":"1999","unstructured":"Bammer G, Dobler-Mikola A, Fleming PM, Strang J, Uchtenhagen A. The Heroin Prescribing debate: integrating Science and Politics. Science. 1999;284(5418):1277\u20138.","journal-title":"Science"},{"issue":"4","key":"1102_CR31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1360-0443.1993.tb02053.x","volume":"88","author":"G Bammer","year":"1993","unstructured":"Bammer G. Should the controlled provision of heroin be a treatment option? Australian feasibility considerations. Addiction (Abingdon England). 1993;88(4):467\u201375.","journal-title":"Addiction (Abingdon England)"},{"key":"1102_CR32","unstructured":"Bammer G, McDonald D. Feasibility Research into the Controlled Availability of Opioids Stage 2. 1992;2."},{"key":"1102_CR33","unstructured":"Bammer G, McDonald DN. Feasibility Research into the Controlled Availability of Opioids Stage 2. Issues for designing and evaluating a \u2018heroin trial\u2019. Three discussion papers. In: Working Paper Number 8. Canberra: National Centre for Epidemiology and Population Health; 1994."},{"key":"1102_CR34","unstructured":"Bammer G, Gerrard G. Heroin Treatment \u2013 New Alternatives, Proceedings of a one\u2013day seminar. In. Becker House, Canberra, November 1991; 1992."},{"issue":"1","key":"1102_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-023-00585-4","volume":"19","author":"S Beaumont","year":"2024","unstructured":"Beaumont S, Magel T, MacDonald S, Harrison S, Schechter M, Oviedo-Joekes E. Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT). Subst Abuse Treat Prev Policy. 2024;19(1):1.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1102_CR36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.drugpo.2019.01.026","volume":"71","author":"V Belackova","year":"2019","unstructured":"Belackova V, Salmon AM, Jauncey M, Bell J. Learning from the past, looking to the future - is there a place for injectable opioid treatment among Australia\u2019s responses to opioid misuse? Int J Drug Policy. 2019;71:164\u20138.","journal-title":"Int J Drug Policy"},{"key":"1102_CR37","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/S0924-977X(10)70001-8","volume":"20","author":"P Blanken","year":"2010","unstructured":"Blanken P, van den Brink W, Hendriks VM, Huijsman IA, Klous MG, Rook EJ, Wakelin JS, Barendrecht C, Beijnen JH, van Ree JM. Heroin-assisted treatment in the Netherlands: history, findings, and international context. Eur Neuropsychopharmacol. 2010;20:S105\u201358.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1102_CR38","doi-asserted-by":"crossref","unstructured":"Bowles J, Mansoor M, Werb D, Kerr T, Bardwell G. A qualitative assessment of tablet injectable opioid agonist therapy (TiOAT) in rural and smaller urban British Columbia, Canada: motivations and initial impacts. J Subst Use Addict Treat. 2024;157.","DOI":"10.1016\/j.josat.2023.209185"},{"issue":"4","key":"1102_CR39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1192\/pb.29.4.126","volume":"29","author":"T Carnwath","year":"2005","unstructured":"Carnwath T. Heroin prescription: a limited but valuable role. Psychiatr Bull. 2005;29(4):126\u20137.","journal-title":"Psychiatr Bull"},{"issue":"1","key":"1102_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13722-023-00428-4","volume":"18","author":"S Dobischok","year":"2023","unstructured":"Dobischok S, Carvajal JR, Turner K, Jaffe K, Lehal E, Blawatt S, Redquest C, Baltzer Turje R, McDougall P, Koch B, et al. It feels like I\u2019m coming to a friend\u2019s house: an interpretive descriptive study of an integrated care site offering iOAT (Dr. Peter Centre). Addict Sci Clin Pract. 2023;18(1):73.","journal-title":"Addict Sci Clin Pract"},{"key":"1102_CR41","doi-asserted-by":"publisher","first-page":"103948","DOI":"10.1016\/j.drugpo.2022.103948","volume":"112","author":"S Dobischok","year":"2023","unstructured":"Dobischok S, Metcalfe R, Matzinger E, Palis H, Marchand K, Harrison S, MacDonald S, Byres D, Schechter M, Bansback N, et al. Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: development of a person-centered scale (best-worst scaling). Int J Drug Policy. 2023;112:103948.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1102_CR42","doi-asserted-by":"publisher","first-page":"E115","DOI":"10.9778\/cmajo.20200021","volume":"9","author":"E Eydt","year":"2021","unstructured":"Eydt E, Glegg S, Sutherland C, Meador K, Trew M, Perreault M, Goyer M-E, Le Foll B, Turnbull J, Fairbairn N. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans. CMAJ open. 2021;9(1):E115\u201324.","journal-title":"CMAJ open"},{"issue":"1","key":"1102_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/29767342231210552","volume":"45","author":"AD Fox","year":"2023","unstructured":"Fox AD, Riback L, Perez-Correa A, Ohlendorf E, Ghiroli M, Behrends CN, L\u00f3pez-Castro T. High interest in Injectable Opioid Agonist Treatment with Hydromorphone among Urban Syringe Service Program participants. Subst Use Addict J. 2023;45(1):44\u201353.","journal-title":"Subst Use Addict J"},{"issue":"1","key":"1102_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000535416","volume":"30","author":"Z Friedmann","year":"2023","unstructured":"Friedmann Z, Binder A, Kinkel H-T, K\u00fchner C, Zsolnai A, Mick I. Exploring patients\u2019 perceptions on Injectable Opioid Agonist Treatment: influences on treatment initiation and implications for practice. Eur Addict Res. 2023;30(1):32\u201342.","journal-title":"Eur Addict Res"},{"issue":"1","key":"1102_CR45","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12954-023-00896-6","volume":"20","author":"Z Friedmann","year":"2023","unstructured":"Friedmann Z, Kinkel H-T, K\u00fchner C, Zsolnai A, Mick I, Binder A. Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities. Harm Reduct J. 2023;20(1):162.","journal-title":"Harm Reduct J"},{"key":"1102_CR46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1477-7517-6-2","volume":"6","author":"CC Gartry","year":"2009","unstructured":"Gartry CC, Oviedo-Joekes E, Laliberte N, Schechter MT. NAOMI: the trials and tribulations of implementing a heroin assisted treatment study in North America. Harm Reduct J. 2009;6:2.","journal-title":"Harm Reduct J"},{"issue":"4","key":"1102_CR47","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1192\/pb.29.4.128","volume":"29","author":"E Gilvarry","year":"2005","unstructured":"Gilvarry E. Commentary on: newguidelines for prescribing injectable heroin in opiate addiction. Psychiatr Bull. 2005;29(4):128\u201330.","journal-title":"Psychiatr Bull"},{"key":"1102_CR48","doi-asserted-by":"crossref","unstructured":"Jackson J, Colborne M, Gadimova F, Kennedy MC. They talk to me like a person experiences of people in an Injectable opioid agonist treatment program: a qualitative interpretive description. J Addictions Nurs 2023, 34(3).","DOI":"10.1097\/JAN.0000000000000536"},{"key":"1102_CR49","unstructured":"Krausz M. Heroingest\u00fctzte Behandlung \u2013 Basisversorgung oder Ultima ratio Im Internationalen Vergleich Abh\u00e4ngigkeiten. 2007;13(3):54\u201365."},{"issue":"3","key":"1102_CR50","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1467-842X.2000.tb01565.x","volume":"24","author":"G Lawrence","year":"2000","unstructured":"Lawrence G, Bammer G, Chapman S. Sending the wrong signal\u2019: analysis of print media reportage of the ACT heroin prescription trial proposal, August 1997. Aust N Z J Public Health. 2000;24(3):254\u201364.","journal-title":"Aust N Z J Public Health"},{"issue":"6","key":"1102_CR51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2165\/00023210-200923060-00002","volume":"23","author":"N Lintzeris","year":"2009","unstructured":"Lintzeris N. Prescription of heroin for the management of heroin dependence: current status. CNS Drugs. 2009;23(6):463\u201376.","journal-title":"CNS Drugs"},{"key":"1102_CR52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1477-7517-3-28","volume":"3","author":"N Lintzeris","year":"2006","unstructured":"Lintzeris N, Strang J, Metrebian N, Byford S, Hallam C, Lee S, Zador D, Group R. Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK. Harm Reduct J. 2006;3:28.","journal-title":"Harm Reduct J"},{"issue":"2","key":"1102_CR53","first-page":"200","volume":"31","author":"T Magel","year":"2024","unstructured":"Magel T, Matzinger E, Blawatt S, Harrison S, MacDonald S, Amara S, Metcalfe R, Bansback N, Byres D, Schechter M, et al. How injectable opioid agonist treatment (iOAT) care could be improved? Service providers and stakeholders\u2019 perspectives. Drugs: Educ Prev Policy. 2024;31(2):200\u201311.","journal-title":"Drugs: Educ Prev Policy"},{"issue":"4","key":"1102_CR54","doi-asserted-by":"publisher","first-page":"606","DOI":"10.17269\/s41997-020-00315-4","volume":"111","author":"N Maghsoudi","year":"2020","unstructured":"Maghsoudi N, Bowles J, Werb D. Expanding access to diacetylmorphine and hydromorphone for people who use opioids in Canada. Can J Public Health = Revue canadienne de sante Publique. 2020;111(4):606\u20139.","journal-title":"Can J Public Health = Revue canadienne de sante Publique"},{"issue":"2","key":"1102_CR55","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jsat.2006.04.007","volume":"31","author":"JC March","year":"2006","unstructured":"March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 2006;31(2):203\u201311.","journal-title":"J Subst Abuse Treat"},{"key":"1102_CR56","doi-asserted-by":"crossref","unstructured":"March JC, Oviedo-Joekes E, Romero M, Gomez M, Rodriguez S, Leon MI, Rodriguez C, Equipo P. [The experimental drug prescription program in Andalusia [PEPSA]: procedure for recruiting participants]. Captacion de participantes en el programa experimental de prescripcion de estupefacientes en Andalucia (PEPSA). 2004;18(3):245\u2013247.","DOI":"10.1157\/13063102"},{"issue":"1","key":"1102_CR57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13011-020-0253-y","volume":"15","author":"K Marchand","year":"2020","unstructured":"Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1):7.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1102_CR58","doi-asserted-by":"crossref","unstructured":"Mayer S, Fowler A, Brohman I, Fairbairn N, Boyd J, Kerr T, McNeil R. Motivations to initiate injectable hydromorphone and diacetylmorphine treatment: a qualitative study of patient experiences in Vancouver, Canada. Int J Drug Policy. 2020;85.","DOI":"10.1016\/j.drugpo.2020.102930"},{"key":"1102_CR59","doi-asserted-by":"publisher","first-page":"104054","DOI":"10.1016\/j.drugpo.2023.104054","volume":"117","author":"S Mayer","year":"2023","unstructured":"Mayer S, Boyd J, Fairbairn N, Chapman J, Brohman I, Jenkins E, McNeil R. Women\u2019s experiences in injectable opioid agonist treatment programs in Vancouver, Canada. Int J Drug Policy. 2023;117:104054.","journal-title":"Int J Drug Policy"},{"key":"1102_CR60","doi-asserted-by":"publisher","first-page":"109869","DOI":"10.1016\/j.drugalcdep.2023.109869","volume":"247","author":"R McNair","year":"2023","unstructured":"McNair R, Monaghan M, Montgomery P. Heroin assisted treatment for key health outcomes in people with chronic heroin addictions: a context-focused systematic review. Drug Alcohol Depend. 2023;247:109869.","journal-title":"Drug Alcohol Depend"},{"key":"1102_CR61","first-page":"45","volume":"25","author":"M Meyer","year":"2023","unstructured":"Meyer M, Haltmayer H, Krausz M. Intraven\u00f6se Opioid-Agonistentherapie (OAT) in \u00d6sterreich? - intravenous opioid agonist therapy (OAT) in Austria? Suchtmedizin Forschung Und Praxis. 2023;25:45\u20136.","journal-title":"Suchtmedizin Forschung Und Praxis"},{"issue":"4","key":"1102_CR62","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jsat.2010.03.003","volume":"38","author":"E Oviedo-Joekes","year":"2010","unstructured":"Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Nosyk B, Krausz M, Anis A, Schechter MT. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study. J Subst Abuse Treat. 2010;38(4):408\u201311.","journal-title":"J Subst Abuse Treat"},{"key":"1102_CR63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1747-597X-10-3","volume":"10","author":"E Oviedo-Joekes","year":"2015","unstructured":"Oviedo-Joekes E, Marchand K, Lock K, MacDonald S, Guh D, Schechter MT. The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency. Subst Abuse Treat Prev Policy. 2015;10:3.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"1102_CR64","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12913-023-09558-6","volume":"23","author":"E Oviedo-Joekes","year":"2023","unstructured":"Oviedo-Joekes E, Dobischok S, Carvajal J, MacDonald S, McDermid C, Klakowicz P, Harrison S, LaJeunesse J, Chow N, Brown M, et al. Clients\u2019 experiences on North America\u2019s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study. BMC Health Serv Res. 2023;23(1):553.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1102_CR65","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/14659891.2022.2120433","volume":"29","author":"HL Poulter","year":"2024","unstructured":"Poulter HL, Moore H, Crow R, Ahmed D, Walker T. Diamorphine assisted treatment in Middlesbrough: a UK drug treatment case study. J Subst Use. 2024;29(1):61\u20137.","journal-title":"J Subst Use"},{"issue":"1","key":"1102_CR66","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12954-023-00785-y","volume":"20","author":"F Riley","year":"2023","unstructured":"Riley F, Harris M, Poulter HL, Moore HJ, Ahmed D, Towl G, Walker T. This is hardcore\u2019: a qualitative study exploring service users\u2019 experiences of heroin-assisted treatment (HAT) in Middlesbrough, England. Harm Reduct J. 2023;20(1):66.","journal-title":"Harm Reduct J"},{"key":"1102_CR67","doi-asserted-by":"crossref","unstructured":"Springer A. Heroingest\u00fctzte Behandlung: drogenpolitische Aspekte. In: Opiatabh\u00e4ngigkeit: Interdisziplin\u00e4re Aspekte f\u00fcr die Praxis. edn. Edited by Beubler E, Haltmayer H, Springer A. Vienna: Springer Vienna; 2007: 79\u201390.","DOI":"10.1007\/978-3-211-69389-6_8"},{"issue":"12","key":"1102_CR68","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/15265161.2017.1388449","volume":"17","author":"D Steel","year":"2017","unstructured":"Steel D, Marchand K, Oviedo-Joekes E. Our life depends on this drug: competence, inequity, and Voluntary Consent in clinical trials on supervised injectable opioid assisted treatment. Am J Bioeth. 2017;17(12):32\u201340.","journal-title":"Am J Bioeth"},{"issue":"1","key":"1102_CR69","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1360-0443.2009.02741.x","volume":"105","author":"A Uchtenhagen","year":"2010","unstructured":"Uchtenhagen A. Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction (Abingdon England). 2010;105(1):29\u201337.","journal-title":"Addiction (Abingdon England)"},{"issue":"3","key":"1102_CR70","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1177\/002204269902900309","volume":"29","author":"W van den Brink","year":"1999","unstructured":"van den Brink W, Hendriks VM, van Ree JM. Medical co-prescription of heroin to chronic, treatment-resistant methadone patients in the Netherlands. J Drug Issues. 1999;29(3):587\u2013608.","journal-title":"J Drug Issues"},{"issue":"7","key":"1102_CR71","doi-asserted-by":"publisher","first-page":"348","DOI":"10.5694\/j.1326-5377.1997.tb125096.x","volume":"167","author":"AD Wodak","year":"1997","unstructured":"Wodak AD. Public health and politics: the demise of the ACT heroin trial. Med J Aust. 1997;167(7):348\u20139.","journal-title":"Med J Aust"},{"key":"1102_CR72","unstructured":"ZIS. Das bundesdeutsche Modellprojekt zur heroingest\u00fctzten Behandlung Opiatabh\u00e4ngiger \u2013 eine multizentrische, randomisierte, kontrollierte Therapiestudie. Abschlussbericht der klinischen Vergleichsstudie zur Heroin- und Methadonbehandlung. In. Hamburg: Zentrum f\u00fcr Interdisziplin\u00e4re Suchtforschung (ZIS) der Universit\u00e4t Hamburg; 2006."},{"issue":"5","key":"1102_CR73","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1192\/bjp.bp.112.111583","volume":"203","author":"S Byford","year":"2013","unstructured":"Byford S, Barrett B, Metrebian N, Groshkova T, Cary M, Charles V, Lintzeris N, Strang J. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. Br J Psychiatry. 2013;203(5):341\u20139.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"1102_CR74","doi-asserted-by":"publisher","first-page":"E317","DOI":"10.1503\/cmaj.110669","volume":"184","author":"B Nosyk","year":"2012","unstructured":"Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, Meikleham E, Schechter MT, Anis AH. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. Can Med Assoc J. 2012;184(6):E317.","journal-title":"Can Med Assoc J"},{"issue":"3","key":"1102_CR75","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1353\/ken.2021.0022","volume":"31","author":"D Steel","year":"2021","unstructured":"Steel D, Tekin S. Can Treatment for Substance Use Disorder prescribe the same substance as that used? The case of Injectable Opioid Agonist Treatment. Kennedy Inst Ethics J. 2021;31(3):271\u2013301.","journal-title":"Kennedy Inst Ethics J"},{"issue":"3","key":"1102_CR76","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/jme.19.3.175","volume":"19","author":"R Ostini","year":"1993","unstructured":"Ostini R, Bammer G, Dance PR, Goodin RE. The ethics of experimental heroin maintenance. J Med Ethics. 1993;19(3):175.","journal-title":"J Med Ethics"},{"issue":"7503","key":"1102_CR77","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/bmj.330.7503.1297","volume":"330","author":"MGW Dijkgraaf","year":"2005","unstructured":"Dijkgraaf MGW, van der Zanden BP, de Borgie CAJM, Blanken P, van Ree JM, van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ (Clinical Res ed). 2005;330(7503):1297.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"9","key":"1102_CR78","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2215-0366(22)00241-3","volume":"9","author":"RM Krausz","year":"2022","unstructured":"Krausz RM, Westenberg JN, Meyer M, Choi F. The upcoming synthetic ultrapotent opioid wave as a foreseeable disaster. Lancet Psychiatry. 2022;9(9):699\u2013700.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1102_CR79","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12954-017-0178-6","volume":"14","author":"DC Des Jarlais","year":"2017","unstructured":"Des Jarlais DC. Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduct J. 2017;14(1):51.","journal-title":"Harm Reduct J"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01102-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01102-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01102-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T16:03:56Z","timestamp":1733328236000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01102-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1102"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01102-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All co-authors have seen and agree with the contents of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}